{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T03:59:09Z","timestamp":1778126349687,"version":"3.51.4"},"reference-count":25,"publisher":"FapUNIFESP (SciELO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An. Bras. Dermatol."],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:p>FUNDAMENTOS: O cetuximab e o erlotinib, inibidores do receptor do factor de crescimento epid\u00e9rmico, provocam frequentemente reac\u00e7\u00f5es cut\u00e2neas adversas peculiares. OBJETIVOS: Caracterizar do ponto de vista cl\u00ednico-evolutivo as reac\u00e7\u00f5es cut\u00e2neas adversas e avaliar a sua abordagem terap\u00eautica. METODOLOGIA: Entre mar\u00e7o\/2005 e setembro\/2009 foram seguidos 14 doentes com idade m\u00e9dia de 59,6 anos, em tratamento com cetuximab (7) ou erlotinib (7), por neoplasia pulmonar (10) ou colorrectal (4). Retrospectivamente foi avaliado o padr\u00e3o cl\u00ednico evolutivo de reac\u00e7\u00e3o cut\u00e2nea, o intervalo entre a introdu\u00e7\u00e3o do f\u00e1rmaco e o in\u00edcio dos sintomas e a resposta ao tratamento. RESULTADOS: Doze doentes apresentaram erup\u00e7\u00e3o papulopustulosa predominantemente na face, decote e dorso, em m\u00e9dia 13,5 dias ap\u00f3s o in\u00edcio do f\u00e1rmaco. Efectuaram tratamento oral com minociclina ou doxiciclina e t\u00f3pico com metronidazol, per\u00f3xido de benzo\u00edlo e\/ou corticoide. Ocorreu melhoria das les\u00f5es em todos os doentes. Cinco doentes, em m\u00e9dia oito semanas ap\u00f3s o in\u00edcio da terapia, apresentaram granulomas piog\u00e9nicos periungueais, em quatro casos associados a paron\u00edquia, melhorados com tratamento t\u00f3pico (antibi\u00f3ticos, corticoides e antiss\u00e9pticos). Observou-se xerose em alguns doentes e, de forma isolada, outros efeitos adversos, como telangiectasias e angiomas, altera\u00e7\u00f5es dos cabelos e c\u00edlios e nevos melanoc\u00edticos eruptivos. Na maioria dos doentes, a terap\u00eautica com o inibidor do receptor do factor de crescimento epid\u00e9rmico foi mantida. CONCLUS\u00c3O: Com o crescente uso destas terap\u00eauticas-alvo, torna-se obrigat\u00f3rio reconhecer e tratar os seus efeitos cut\u00e2neos adversos, assegurando uma interven\u00e7\u00e3o atempada de forma a permitir a manuten\u00e7\u00e3o desta terap\u00eautica<\/jats:p>","DOI":"10.1590\/s0365-05962011000300010","type":"journal-article","created":{"date-parts":[[2011,6,30]],"date-time":"2011-06-30T16:34:55Z","timestamp":1309451695000},"page":"483-490","source":"Crossref","is-referenced-by-count":25,"title":["Reac\u00e7\u00f5es cut\u00e2neas adversas aos inibidores do receptor do factor de crescimento epid\u00e9rmico: estudo de 14 doentes"],"prefix":"10.1590","volume":"86","author":[{"given":"Felicidade","family":"Santiago","sequence":"first","affiliation":[{"name":"Universidade de Coimbra, Portugal"}]},{"given":"Margarida","family":"Gon\u00e7alo","sequence":"additional","affiliation":[{"name":"Universidade de Coimbra, Portugal"}]},{"given":"Jos\u00e9 Pedro","family":"Reis","sequence":"additional","affiliation":[{"name":"Universidade de Coimbra, Portugal"}]},{"given":"Am\u00e9rico","family":"Figueiredo","sequence":"additional","affiliation":[{"name":"Universidade de Coimbra, Portugal"}]}],"member":"530","reference":[{"issue":"1","key":"ref1","first-page":"16","article-title":"Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors","author":"Deslandres M","year":"2008","journal-title":"Ann Dermatol Venereol","ISSN":"https:\/\/id.crossref.org\/issn\/0151-9638","issn-type":"print"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert S","year":"2005","journal-title":"Ann Oncol","ISSN":"https:\/\/id.crossref.org\/issn\/0923-7534","issn-type":"print"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaad.2006.04.062","article-title":"Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients","volume":"55","author":"Ro\u00e9 E","year":"2006","journal-title":"J Am Acad Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/0190-9622","issn-type":"print"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors","volume":"55","author":"Agero AL","year":"2006","journal-title":"J Am Acad Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/0190-9622","issn-type":"print"},{"key":"ref5","first-page":"1","article-title":"Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective","volume":"12","author":"Lacouture ME","year":"2007","journal-title":"Skin Therapy Lett"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2006.09.005","article-title":"Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management","volume":"56","author":"Hu JC","year":"2007","journal-title":"J Am Acad Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/0190-9622","issn-type":"print"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/1523-1747.ep12874601","article-title":"Immunolocalization of epidermal growth factor receptors in normal developing human skin","volume":"94","author":"Nanney LB","year":"1990","journal-title":"J Invest Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/0022-202X","issn-type":"print"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture ME","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1677\/erc.1.00600","article-title":"Epidermal growth factor receptor inhibition strategies in oncology","volume":"11","author":"Harari PM","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3747\/co.v16i1.361","article-title":"Management of skin rash during egfr-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations","volume":"16","author":"Melosky B","year":"2009","journal-title":"Curr Oncol"},{"key":"ref11","first-page":"296","article-title":"Epidermal growth factor receptor inhibitors side effects","volume":"97","author":"Guhl G","year":"2006","journal-title":"Actas Dermosifiliogr","ISSN":"https:\/\/id.crossref.org\/issn\/0001-7310","issn-type":"print"},{"key":"ref12","first-page":"451","article-title":"Reac\u00e7\u00f5es Cut\u00e2neas Adversas aos Inibidores do EGFR: Receptor do Factor de Crescimento Epid\u00e9rmico","volume":"65","author":"Varela P","year":"2007","journal-title":"Soc Port Dermatol Venereol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous sideeffects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert C","year":"2005","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaad.2006.06.046","article-title":"Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy","volume":"56","author":"Dewitt CA","year":"2007","journal-title":"J Am Acad Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/0190-9622","issn-type":"print"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous sideeffects in cancer patients treated with the antiepidermal growth factor receptor anti body C225","volume":"144","author":"Busam KJ","year":"2001","journal-title":"Br J Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/0007-0963","issn-type":"print"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11523-009-0114-0","article-title":"Skin toxicities associated with epidermal growth factor receptor inhibitors","volume":"4","author":"Li T","year":"2009","journal-title":"Target Oncol"},{"key":"ref17","first-page":"23","article-title":"Cutaneous side effects in nonsmall cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor","volume":"84","author":"Lee MW","year":"2004","journal-title":"Acta Derm Venereol","ISSN":"https:\/\/id.crossref.org\/issn\/0001-5555","issn-type":"print"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaad.2006.09.013","article-title":"Nail toxicity associated with epidermal growth factor receptor inhibitor therapy","volume":"56","author":"Fox LP","year":"2007","journal-title":"J Am Acad Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/0190-9622","issn-type":"print"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2133.2009.09214.x","article-title":"Cutaneous sideeffects in patients on long-term treatment with epidermal growth factor receptor inhibitors","volume":"161","author":"Osio A","year":"2009","journal-title":"Br J Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/0007-0963","issn-type":"print"},{"key":"ref20","first-page":"672","article-title":"Eruptive nevi associated with sorafenib treatment","volume":"135","author":"Bennani-Lahlou M","year":"2008","journal-title":"Ann Dermatol Venereol","ISSN":"https:\/\/id.crossref.org\/issn\/0151-9638","issn-type":"print"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaad.2008.06.034","article-title":"Dermatologic symptoms associated with the multikinase inhibitor sorafenib","volume":"60","author":"Robert C","year":"2009","journal-title":"J Am Acad Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/0190-9622","issn-type":"print"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaad.2006.11.004","article-title":"Epidermal growth factor receptor inhibitors: a new era of drug reactions in a new era of cancer therapy","volume":"56","author":"Cowen EW","year":"2007","journal-title":"J Am Acad Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/0190-9622","issn-type":"print"},{"key":"ref23","first-page":"22","article-title":"Clinical management of EGFRI dermatologic toxicities: the European perspective","volume":"21","author":"Segaert S","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1684\/ejd.2009.0650","article-title":"Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients","volume":"19","author":"de Noronha e Menezes NM","year":"2009","journal-title":"Eur J Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/1167-1122","issn-type":"print"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1634\/theoncologist.12-5-610","article-title":"Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management","volume":"12","author":"Lynch TJ JR","year":"2007","journal-title":"Oncologist","ISSN":"https:\/\/id.crossref.org\/issn\/1083-7159","issn-type":"print"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abd\/v86n3\/v86n3a10.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:00:40Z","timestamp":1747666840000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0365-05962011000300010&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0365-05962011000300010"],"URL":"https:\/\/doi.org\/10.1590\/s0365-05962011000300010","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}